[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad de la Sabana\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":159},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,82,109,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100616741","the-extended-study-of-prevalence-of-infection-in-intensive-care-iv-100616741",false,"NCT07309549","The Extended Study of Prevalence of Infection in Intensive Care IV","The Extended Study of Prevalence of Infection in Intensive Care IV (EPIC IV)","EPIC IV","Inclusion Criteria:\n\n* All adult patients (\\>18 years) treated in the participating ICUs on the study day.\n\nExclusion Criteria:\n\n* Patients under 18 years","ALL","18 Years",{"count":20,"type":21},10000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how common infections are in intensive care units (ICUs) around the world and how they are treated. The study will look at all adults in the ICU during a single 24-hour period. The main questions it aims to answer are:\n\n* What types of infections and antibiotic-resistant bacteria are most common in ICUs worldwide?\n* How do resistance patterns affect how participants are treated and how they recover?\n\nHow are antibiotics used in ICUs, and how do hospitals practice antibiotic stewardship?\n\n* What organ support treatments do participants with infections receive?\n* What are the outcomes of participants with severe infections, including survival at hospital discharge (up to 60 days)?\n\nResearchers will compare ICUs across regions and income levels to see how infection patterns, treatments, and outcomes differ around the world.\n\nParticipants will:\n\n* Be counted if they are present in the ICU at any time during the study day.\n* Have information collected from their medical record about their health, the infection they may have, treatments they receive, and their outcome at ICU and hospital discharge (up to 60 days).\n\nBecause this is an observational study, participants will not receive any new treatments as part of the study.",[25,26],"Sepsis","Infection",[28,29,30,31,32,33],"Intensive Care Unit","Critical Illness","Severe Infection","Organ Dysfunction","ICU Outcomes","Global Prevalence","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":21},"2027-02-01",{"date":42,"type":21},"2027-06",{"name":44,"class":45},"Universidad de la Sabana","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100639783","nursing-intervention-for-adaptation-after-myocardial-revascularization-100639783","NCT07576569","Nursing Intervention for Adaptation After Myocardial Revascularization","Preliminary Effectiveness of a Nursing Intervention Aimed at Improving Adaptation in Patients and Their Caregivers During the Outpatient Postoperative Period Following Myocardial Revascularization","ADAPT-CABG","Inclusion Criteria:\n\n* Adults aged 18 years or older who have undergone myocardial revascularization surgery, completed the immediate postoperative in-hospital period without major complications, and have been discharged for outpatient management according to institutional protocols\n* Patients who, at the time of discharge, do not require ventilatory support, invasive hemodynamic support, or continuous monitoring, and present documented clinical stability\n* Presence of an identified primary caregiver actively involved in the home care process during the outpatient postoperative period\n* Preserved cognitive capacity in both patient and caregiver, allowing understanding of instructions, participation in the intervention, and completion of assessment instruments\n* Written informed consent provided by both patient and caregiver\n\nExclusion Criteria:\n\n* Patients presenting severe postoperative complications, such as deep surgical site infection, persistent hemodynamic instability, major neurological events, or readmission to the intensive care unit at the start of the intervention Patients with moderate to severe cognitive impairment, decompensated psychiatric disorders, or neurological conditions that limit understanding, communication, or active participation\n* Caregivers with physical, cognitive, or emotional limitations that compromise the effective performance of the caregiving role during the follow-up period\n* Patients without a clearly identified support network or without an available primary caregiver to participate in the study\n* Concurrent participation in other clinical, educational, or psychosocial intervention studies that may interfere with the proposed intervention\n* Language or cultural barriers that prevent understanding of the intervention content or interaction with the research team, without adequate mediation",{"count":55,"type":21},40,"INTERVENTIONAL",[58],"NA","Introduction: Myocardial revascularization is an essential procedure for patients with cardiovascular disease. Its recovery in the outpatient setting involves significant challenges for both the patient and the caregiver. This recovery phase may generate physical, emotional, and psychological complications that require an effective adaptation process of the patient-caregiver dyad to ensure successful recovery and improved quality of life.\n\nObjective: To evaluate the preliminary effectiveness of a nursing intervention aimed at improving adaptation in the patient-caregiver dyad during the outpatient postoperative period following myocardial revascularization, compared with usual care, in Bucaramanga during the period 2026-2027.\n\nMaterials and Methods: A pilot randomized controlled trial will be conducted to develop and evaluate a novel nursing intervention aimed at promoting adaptation in patients undergoing outpatient postoperative myocardial revascularization and their caregivers. The intervention will be designed and its feasibility, acceptability, and preliminary effectiveness will be assessed. Data analysis will be performed using descriptive and inferential statistical methods, considering the distribution and behavior of the data.\n\nExpected Results: The study is expected to assess the preliminary effectiveness of the proposed intervention through the integration of theoretical and empirical components.",[61,62,63,64],"Coronary Artery Disease","Myocardial Revascularization","Postoperative Recovery After Cardiac Surgery","Nursing Care",[62,66,67,68,69,70,71,72],"Nursing Intervention","Patient-Caregiver Dyad","Adaptation","Postoperative Recovery","Cardiovascular Disease","Randomized Controlled Trial","Outpatient Care","2026-05-02",{"date":75,"type":38},"2026-05-08",{"date":77,"type":21},"2027-01",{"date":79,"type":21},"2027-12",{"name":44,"class":45},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":56,"phases":92,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":81},"100629700","mhealth-intervention-to-support-self-care-during-the-hospital-to-home-transition-in-individuals-with-heart-failure-100629700","NCT07478081","mHealth Intervention to Support Self-care During the Hospital to Home Transition in Individuals With Heart Failure","Evaluation of the Feasibility, Usability, and Preliminary Effects of an mHealth Intervention Complementary to Usual Care in Individuals With Heart Failure: Protocol for a Pilot Randomized Clinical Trial","HF-mHealth","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of heart failure (NYHA Class II or III)\n* Clinically stable at discharge (no IV inotropes within 48 hours; hemodynamically stable)\n* Ownership of compatible smartphone (Android\u002FiOS)\n* Basic digital literacy\n* Availability of informal caregiver willing to support the process\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C 6 months\n* Severe cognitive impairment (MMSE \\\u003C24 or documented dementia)\n* Inability to provide informed consent\n* Participation in another interventional study",{"count":91,"type":21},30,[58],"This study is a pilot randomized controlled trial designed to evaluate the feasibility, acceptability, usability, and preliminary efficacy of a mobile health (mHealth) educational self-management intervention for individuals with heart failure during the transition from hospital to home. Participants will be randomly assigned in a 1:1 ratio to receive either usual care alone or usual care plus the mHealth intervention.\n\nThe mobile application is designed to support heart failure self-care through tailored educational content, symptom self-monitoring, automated feedback, behavioral reinforcement messages, caregiver involvement, and secure communication with the healthcare team. The application is educational in nature and does not replace standard medical treatment.\n\nA total of 30 participants will be enrolled and followed for 60 days after hospital discharge, with outcome assessments conducted at 30 and 60 days. Primary outcomes focus on feasibility, technology acceptance, and usability of the intervention. Secondary exploratory outcomes include changes in self-care behaviors, functional status, heart failure related hospital readmissions and natriuretic peptide levels. Results from this pilot study will inform the design of a future definitive randomized controlled trial.",[95,96,97],"Heart Failure","Self-care","Transitional Care",[99,95,97,100,101,96],"mHealth","Patient Education","Self-Management","2026-03-17",{"date":104,"type":38},"2026-03-20",{"date":106,"type":21},"2026-03",{"date":42,"type":21},{"name":44,"class":45},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":81},"100616091","epidemiology-and-current-practices-in-severe-community-acquired-pneumonia-100616091","NCT07301099","Epidemiology and Current Practices in Severe Community-Acquired Pneumonia","Epidemiology and Current Practices in Severe Community-Acquired Pneumonia (PLENITUDE)","PLENITUDE","Inclusion Criteria:\n\n* Adults aged 18 years or older are hospitalised with a clinical diagnosis of sCAP according to the American Thoracic Society\u002FInfectious Diseases Society of America (ATS\u002FIDSA) criteria.16\n* Admission to participating hospitals or ICUs during the study period.\n* Provision of informed consent by the patient or legally authorised representative for those centres collecting biological samples. Data-only participants will not be required to sign informed consent.\n\nExclusion Criteria:\n\n* Paediatric population (\\\u003C18 years old)\n* Pneumonia acquired in the hospital setting (i.e., nosocomial or hospital-acquired pneumonia).\n* Insufficient clinical information to confirm the diagnosis of sCAP.\n* Immunosuppression: i.e. Active cancer, hematopoietic cell transplant, solid organ transplant recipients, HIV diagnosed patients regardless of CD4 cell count, chronic immunosuppression with corticosteroids, inborn errors of immunity.",{"count":118,"type":21},2588,"The goal of this observational study is to learn more about severe community-acquired pneumonia (sCAP) in adults who need hospital or intensive care. This type of pneumonia starts outside the hospital and can quickly become life-threatening. The study aims to understand how people with sCAP are cared for in different parts of the world and how these differences relate to their recovery.\n\n* The main questions this study aims to answer are:\n* What are the characteristics, treatments, and outcomes of adults with sCAP?\n* How closely do hospitals follow international guidelines for diagnosing and treating sCAP?\n* What factors are linked to worse outcomes, such as the need for a ventilator or risk of death?\n\nThis study will not test any new drugs or procedures. Instead, researchers will observe the care that participants already receive as part of their normal treatment. Hospitals in many countries will take part, including centres in Europe, North America, Latin America, Asia, Africa, and Oceania. This global participation will help show how sCAP affects people in different health systems and communities.\n\nParticipants will be adults who arrive at a hospital or intensive care unit with severe pneumonia. Most information will come from medical records, such as symptoms, test results, treatments given, and how participants respond to care. In some hospitals with special laboratory capacity, additional blood or breathing samples may be collected to study how the body fights infection.\n\nNo extra visits are required for routine data-only participants. In sites that collect samples, these will usually be taken at the same time as routine medical care to avoid extra procedures. Researchers will also ask about recovery after hospital discharge at 60 days, 6 months, and 12 months. These follow-ups will help us understand long-term health, complications, and quality of life after sCAP.\n\nBy collecting information from a large number of hospitals around the world, this study hopes to identify patterns that can help improve diagnosis, treatment, and survival for people with severe pneumonia. The findings may also help health care teams and public health leaders update treatment guidelines and strengthen care for future patients.",[121],"Severe Community-acquired Pneumonia (sCAP)",[123,124,125,126],"Pneumonia","Respiratory Tract Infections","Community-Acquired Pneumonia","Respiratory Tract Diseases","2026-01-14",{"date":129,"type":38},"2026-01-15",{"date":131,"type":21},"2026-02-01",{"date":133,"type":21},"2027-08-31",{"name":44,"class":45},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":142,"enrollmentInfo":4,"targetDuration":4,"studyType":143,"phases":4,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":154,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":158,"locationsCount":81},"100395703","infusion-of-allogeneic-mesenchymal-stem-cells-in-patients-with-diffuse-cutaneous-systemic-sclerosis-with-refractory-pulmonary-involvement-100395703","NCT04432545","Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement","Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment","Inclusion Criteria:\n\n* Age\\> 18 years and \\\u003C65 years.• Established diagnosis of systemic sclerosis according to the criteria of theAmerican College of Rheumatology• SSc of poor prognosis, involving life-threatening severe visceralinvolvement (cardiac or pulmonary hypertension ), lack of response toconventional immunosuppressive therapy used in severe forms of thedisease according to the European recommendations of EUSTAR and EBMT, relying on high doses of IV cyclophosphamide (either in monthlybolus for at least six months); or SSc with life-threatening pulmonaryhypertension. Patients may or may not have pulmonary fibrosis.• Signed informed consent.• Presence of a consenting MSC donor• Affiliation to social security\n\nExclusion Criteria:\n\n* Pregnancy or absence of appropriate contraception throughout the study.• Pulmonary artery systolic pressure (PASP) \\>75mmHg (onechocardiography or after right heart catheterization);- Theorical DLCO \\\u003C30%• Calculated creatinine clearance \\\u003C30 ml\u002Fmn\u002Fm2• Clinical sign of a congestive heart failure refractory ;• Left ventricular ejection fraction \\\u003C35% at myocardial scintigraphy orechocardiography;• Chronic atrial fibrillation requiring oral anticoagulant therapy;• Uncontrolled ventricular arrhythmia;• Pericardial effusion with hemodynamic compromise assessed byechocardiography.• Hepatic impairment defined as a persistent increase in transaminases orbilirubin to 3 times normal.• Psychiatric disorders, including drug taking and alcohol abuse.• Active neoplasia or concomitant myelodysplasia, antecedent of neoplasia.• Bone marrow failure defined by neutropenia \\\u003C0.5 x 109 \u002F L,thrombocytopenia \\\u003C50 x 109 \u002F L, anemia \\\u003C8 g \u002F dL, CD4 lymphopenia \\\u003C200x 106 \u002F L.• Uncontrolled systemic hypertension.• Uncontrolled acute or chronic infection, HIV1, 2 or HTLV-1, 2seropositivity.• Chronic hepatitis B or C active.• Significant exposure to bleomycin, toxic oils, vinyl chloride,trichloroethylene or silica; eosinophilia-myalgia syndrome, eosinophiliafasciitis.• Risk of poor patient compliance","65 Years","EXPANDED_ACCESS","Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years. The disease causessevere limitation in quality of life ranging from functional limitation to depression. Up to 20% of patients will be refractory to conventional treatment with diseasemodifying anti-rheumatic drugs (DMARDs) and cyclophosphamide therapy.This favors the progression to visceral involvement including gastrointestinal,lung and pulmonary hypertension. The latter being a poor prognostic factor,increases mortality in this group of patients and drastically affects their qualityof life. For this reason, different therapeutic options have been considered including cell transplantation and Stem Cell use. Among the options that have been studied so far are stromal mesenchymal cells from Wharton ́s jelly. These have been used in intravenous infusion or direct application in different disease scenarios ranging from vascular involvement to interstitial lung involvement and cases of pulmonary hypertension, with promising results in terms of clinical progression,improvement in quality of life and prognostic indices. This therapy has proven to have a significant margin of safety at the time of administration and a low rate of adverse events, a self-limiting fever as the most frequent event. Based on the above and considering the possibility of offering patients without therapeutic alternatives to their disease in addition to palliative options, an intravenous infusion of stromal mesenchymal stem cells from Wharton ́s jellyis proposed for three patients with progressive SSc refractory to conventional therapy with pulmonary involvement due to pulmonary hypertension.\n\nUnder this premise the question posed in our work is; What are the effects of the infusion of allogeneic mesenchymal stromal cells from Wharton ́s jellyin patients with systemic sclerosis refractory to conventional treatment with Methotrexate or Cyclophosphamide in a population of three patients with severe pulmonary involvement due to pulmonary hypertension.",[146,147,148],"Systemic Sclerosis Pulmonary","Pulmonary Hypertension","Pulmonary Fibrosis",[150,151,152,153],"Refractory systemic sclerosis","systemic sclerosis","pulmonary hypertension","mesenchymal stem cells","AVAILABLE","2024-04-04",{"date":157,"type":38},"2024-04-08",{"name":44,"class":45},""]